January 14, 2022
Geron Corporation, a biopharmaceutical company, had just one drug in its pipeline, imetelstat. The complaint for this class action alleges that a Phase 2 clinical trial for the drug produced disappointing results. Despite this, according to the complaint, company insiders sold a large amount of stock without disclosing the results of the trial. This class action brings suit against Geron and its president and CEO, John A. Scarlett, alleging violations of the Securities Exchange Act of 1934, among other things.
Case Event File: Geron Conceals Study Results, Sells Inflated Stock Amended Consolidated ComplaintRelated to: Geron Conceals Study Results, Sells Inflated Stock Class Action